Login to Your Account



Orphan drug firm Versartis joins IPO queue with $80M filing

By Marie Powers
Staff Writer

Wednesday, February 19, 2014
Versartis Inc., which holds worldwide rights to the long-acting recombinant human growth hormone (rHGH) VRS-317, last year suggested it could potentially move the treatment for growth hormone deficiency (GHD) all the way to approval and marketing on its own.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription